French Observatory on the Management of Cardiogenic Shock in 2016

Conditions

Shock, Cardiogenic

Keywords

cardiogenic shock, observatory

Brief summary

Cardiogenic shock (CS) is defined as an organ hypoperfusion secondary to low cardiac output. Catches diagnostic management, and therapeutic monitoring of these patients remain highly variable from one center to another and even from one doctor to another within the same team. The management protocols are often not standardized or non-existent. It appears therefore necessary to make an inventory of the management practices of the CS in France in 2016, prerequisite to a common work of standardization of practices and the creation of specialized networks to support these complex patients.

Detailed description

The Observatory FRENSHOCK proposes to set up a cohort of 500 patients recruited prospectively over a period of 6 months. Patients will be followed up at 1 month and 1 year Patients should have agreed to participate in the observatory, knowing that participation or refusal to participate will not alter the therapeutic attitude of the physician responsible for the patient. The study of phenotypic characteristics will not change the therapeutic approach of the medical teams.

Manzo-Silberman S, Bataille V, Bonello L, Roubille F, Levy B, Lim P, Schurtz G, Letocart P, Chaoui K, Probst V, Ferrari E, Delhaye O, Favory R, Elbaz M, Gerbaud E, Bonnefoy E, Puymirat E, Leurent G, Delmas C.

2025-11-24

10.1016/j.acvd.2025.10.331

Clinical profile, short and long‐term outcomes of non‐ischaemic cardiogenic shock: A FRENSHOCK sub‐analysis

Miloud Cherbi, François Roubille, Édouard Gerbaud, Eric Bonnefoy, Nicolas Lamblin et al. (21 authors)

ESC Heart Failure2025-03-254 citations

10.1002/ehf2.15046

Ventilation strategies in cardiogenic shock: insights from the FRENSHOCK observational registry.

Volle K, Merdji H, Bataille V, Lamblin N, Roubille F, Levy B, Champion S, Lim P, Schneider F, Labbe V, Khachab H, Bourenne J, Seronde MF, Schurtz G, Harbaoui B, Vanzetto G, Quentin C, Combaret N, Marchandot B, Lattuca B, Biendel C, Leurent G, Bonello L, Gerbaud E, Puymirat E, Bonnefoy E, Aissaoui N, Delmas C, FRENSHOCK Investigator.

2024-10-232 citations

10.1007/s00392-024-02551-x

The admission level of CRP during cardiogenic shock is a strong independent risk marker of mortality.

Roubille F, Cherbi M, Kalmanovich E, Delbaere Q, Bonnefoy-Cudraz E, Puymirat E, Schurtz G, Gerbaud E, Bonello L, Lim P, Leurent G, Roubille C, Delmas C.

2024-07-164 citations

10.1038/s41598-024-67556-y

Cardiogenic shock and chronic kidney disease: Dangerous liaisons.

Cherbi M, Bonnefoy E, Puymirat E, Lamblin N, Gerbaud E, Bonello L, Levy B, Lim P, Muller L, Merdji H, Range G, Ferrari E, Elbaz M, Khachab H, Bourenne J, Seronde MF, Florens N, Schurtz G, Labbé V, Harbaoui B, Vanzetto G, Combaret N, Marchandot B, Lattuca B, Leurent G, Faguer S, Roubille F, Delmas C.

2024-03-206 citations

10.1016/j.acvd.2024.01.006

Sex disparities in cardiogenic shock: Insights from the FRENSHOCK registry.

Manzo-Silberman S, Martin AC, Boissier F, Hauw-Berlemont C, Aissaoui N, Lamblin N, Roubille F, Bonnefoy E, Bonello L, Elbaz M, Schurtz G, Morel O, Leurent G, Levy B, Jouve B, Harbaoui B, Vanzetto G, Combaret N, Lattucca B, Champion S, Lim P, Bruel C, Schneider F, Seronde MF, Bataille V, Gerbaud E, Puymirat E, Delmas C, FRENSHOCK investigators.

2024-03-165 citations

10.1016/j.jcrc.2024.154785

Characteristics, management, and mid-term prognosis of older adults with cardiogenic shock admitted to intensive care units: Insights from the FRENSHOCK registry.

Cherbi M, Bouisset F, Bonnefoy E, Lamblin N, Gerbaud E, Bonello L, Levy B, Lim P, Joffre J, Beuzelin M, Roland Y, Niquet L, Favory R, Khachab H, Harbaoui B, Vanzetto G, Combaret N, Marchandot B, Lattuca B, Leurent G, Lairez O, Puymirat E, Roubille F, Delmas C.

2023-11-112 citations

10.1016/j.ijcard.2023.131578

One-year outcomes in cardiogenic shock triggered by supraventricular tachycardia: an analysis of the FRENSHOCK multicenter prospective registry

Miloud Cherbi, Éric Bonnefoy, Nicolas Lamblin, Édouard Gerbaud, Laurent Bonello et al. (26 authors)

Frontiers in Cardiovascular Medicine2023-09-051 citations

10.3389/fcvm.2023.1167738

One-year outcomes in cardiogenic shock triggered by ventricular arrhythmia: An analysis of the FRENSHOCK multicenter prospective registry

Miloud Cherbi, François Roubille, Nicolas Lamblin, Laurent Bonello, Guillaume Leurent et al. (30 authors)

Frontiers in Cardiovascular Medicine2023-01-267 citations

10.3389/fcvm.2023.1092904

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Informed consent * Cardiogenic shock authenticated by the existence of at least one positive test for each of the following three parts: (A) Low cardiac output (1 criterion necessary and sufficient): * Clinic: SBP \<90mmHg and / or need to maintain inotropic or vasopressor to maintain SBP\> 90 mmHg * Echocardiography: IC \<2.2L / min / m2 and / or LVEF \<30% * Hemodynamics by Swan Ganz catheterization or right: IC 2.2 l / min / m2 (B) elevation of pulmonary pressure / left surcharge (1 criterion necessary and sufficient): * Clinical (IVD and abortion); * Radiological (Surcharge on RT or chest CT); * Organic (NTproBNP\> 900pg / ml or BNP\> 400pg / ml); * Echocardiography (E / A\> 2 if LVEF \<45% or E / Ea\> 13 if normal LVEF, or PAPS\> 35mmHg and / or TDE \<150ms and / or Ap-Am\> 30ms and / or E / 2 Vp≥ , 5); * Right Swan Ganz catheterization or (pulmonary capillary pressures\> 15mmHg and / or mPAP\> 25mmHg) (C) Organs malperfusion (1 criterion necessary and sufficient): * Clinic: oliguria \<30ml / kg / h, mottling, consciousness disorders) * Organic: arterial lactate\> 2 mmol / L, liver failure, kidney failure

Exclusion criteria

* Final diagnosis retained other than cardiogenic shock * Cardiac arrest without spontaneous activity in the hospital management * Post-cardiotomy cardiogenic shock * Deprived of liberty patient * Refusal or lack of consent

Design outcomes

Primary

Measure	Time frame	Description
Mortality at day 30	30 days	Death rate at 30 days of follow-up

Secondary

Measure	Time frame	Description
Analysis of mortality at day 30 by subgroup on age, sex, NYHA grade, initial etiology	30 days	Rate of mortality at day 30 distributed by subgroup on age, sex, NYHA grade, initial etiology (Including ischemic versus non-ischemic heart disease, type and assistance and medical treatment)
Mortality at 1 year	1 year	Death rate at 1 year of follow-up

Countries

France

Outcome results